Nicely said Jeff, i agree with your assessment, although I do believe Leo may get a pleasant phone call from the big boys sooner than we think is possible. In my opinion it really depends just how good the P1 data looks when all the dust settles. I could see the think tank at Pfizer or some other large pharma justifying a big buyout as we start phase 2/3 trials given the wealth of data that will be available. I don't think we as ctix shareholders will ever have to worry with completion of phase 3 trials, i believe we'll be bought out before then, but then again I am he eternal optimist.

No matter what, I trust our outstanding CEO and am glad we have such a capable and hard working guy making these decisions and advancing the company forward. Also an added bonus at he has such a finance heavy background, and he knows full well just how much kevetrin should be valued at if it is truly effective in capturing revenue from so many possible different lines of cancer.

We're in good hands, and the trial marches onward. And guess what, April is flying by, and next thing you know ASCO will be here...